5-fluorouracil + carmofur + mitomycin C

This is a combination chemotherapy regimen consisting of three antineoplastic agents: 5-fluorouracil (5FU), carmofur, and mitomycin C. - **5-fluorouracil** is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death in rapidly dividing cells. - **Carmofur** is an oral prodrug of 5-fluorouracil; it is converted into 5FU in the body and exerts similar antitumor effects but with improved gastrointestinal stability and oral bioavailability[6][8]. - **Mitomycin C** is an antitumor antibiotic that acts as a bifunctional alkylating agent after activation in vivo, cross-linking DNA strands and inhibiting DNA synthesis[7][10]. The combination has been studied primarily for colorectal cancer (especially as adjuvant therapy after noncurative resection), where it has shown improved survival rates compared to monotherapy with mitomycin C[2]. Each component targets rapidly dividing tumor cells through distinct but complementary mechanisms.

Other names

5FU + carmofur + mitomycin C5-fluorouracil/carmofur/mitomycin C combination